(Total Views: 332)
Posted On: 04/20/2017 6:47:20 PM
Post# of 72446
CTIX grossly undervalued, market cap comparison:
CTIX: just under 112 million, with 3 drugs in 5 clinical trials.
AVXL, 236 million, 1 risky Alzheimer's drug in Phase 1.
NTRP, 156 million for its Phase 2 Alzheimer's drug.
CTSO, 128 million for a filter to remove toxic stuff from blood
and my favorite:
AXON, 2.17 Billion with a B, for its previously-failed Alzheimer's drug. Wall Street insiders formed and brought this company to market.
As you can see, CTIX is the least valued of these companies, and is the one with by far the most clinical trial successes -- not to mention, not dependent on one drug working.
Will be buying again tomorrow.
CTIX: just under 112 million, with 3 drugs in 5 clinical trials.
AVXL, 236 million, 1 risky Alzheimer's drug in Phase 1.
NTRP, 156 million for its Phase 2 Alzheimer's drug.
CTSO, 128 million for a filter to remove toxic stuff from blood
and my favorite:
AXON, 2.17 Billion with a B, for its previously-failed Alzheimer's drug. Wall Street insiders formed and brought this company to market.
As you can see, CTIX is the least valued of these companies, and is the one with by far the most clinical trial successes -- not to mention, not dependent on one drug working.
Will be buying again tomorrow.
(4)
(0)
